Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) ...

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency (ANVISA) for its single-dose ...

In the evening of April 22, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where it is a finalist for the Best Biotech Award and Best Prophylactic Vaccine Award for VLA15, the ...

Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose ...

Valneva receives Brazilian marketing authorization for single-dose vaccine Ixchiq for prevention of disease caused by chikungunya virus: Saint Herblain, France Wednesday, April 16 ...

will present“Valneva's chikungunya vaccine: key data in support of licensure and plans to confirm effectiveness". On April 24, at 9:00am EST, Valneva's Chief Medical Officer, Dr. Juan Carlos ...

SE ADR (NASDAQ:VALN) stock closed up 12.1% following the announcement that the Brazilian Health Regulatory Agency (ANVISA) has granted the first marketing authorization for its chikungunya vaccine, ...

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...